Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 6/20 | 0.58 |
| ▸ | CA9 | Q16790 | 6/20 | 0.58 |
| ▸ | ACHE | P22303 | 6/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525285 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL133020 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL598026 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL3422180 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5133849 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL2819924 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL5193445 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL15508929 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL22777078 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL29040489 | 1.00 | TDP1 (1.00) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | PAQ Therapeutics Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-119677788-A | Polymer contrast medium | 兴和株式会社 | 2025-03-21 | — | — | CN | disclosed |
| EP-4519273-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | PAQ Therapeutics Inc. (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| CN-107106709-B | Radiopharmaceutical conjugates comprising a metabolite and an EPR agent targeting tumor cells | 南非核能源有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| EP-1083888-A1 | MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999063983-A9 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999063983-A1 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051364-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | TDP1 3827/4885MAOA 4877/4885MAOB 4869/4885 |
| US-12404285-B2 | KRAS G12D proteolysis targeting chimeras | KRAS, NRAS, HRAS | TDP1 3827/4885MAOA 4877/4885MAOB 4869/4885 |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | TDP1 3025/4885MAOA 2748/4885MAOB 2231/4885 |
| US-20240247000-A1 | KRAS G12D Proteolysis Targeting Chimeras | KRAS, NRAS, HRAS | TDP1 3827/4885MAOA 4877/4885MAOB 4869/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | TDP1 2803/4885MAOA 2666/4885MAOB 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.